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The CRISPR-Cas9 system has been employed to
generate mutant alleles in a range of different organ-
isms. However, so far there have not been reports of
use of this system for efficient correction of a genetic
disease. Here we show that mice with a dominant
mutation in Crygc gene that causes cataracts could
be rescued by coinjection into zygotes of Cas9
mRNA and a single-guide RNA (sgRNA) targeting
the mutant allele. Correction occurred via homol-
ogy-directed repair (HDR) based on an exogenously
supplied oligonucleotide or the endogenous WT
allele, with only rare evidence of off-target modi-
fications. The resulting mice were fertile and able to
transmit the corrected allele to their progeny. Thus,
our study provides proof of principle for use of the
CRISPR-Cas9 system to correct genetic disease.
The CRISPR-Cas9 system from bacteria has been recentlyapplied to genome editing in different species, including
Drosophila (Yu et al., 2013), C. elegans (Dickinson et al., 2013;
Friedland et al., 2013), zebrafish (Chang et al., 2013; Hwang
et al., 2013; Jao et al., 2013), mouse (Cho et al., 2013; Cong et al.,
2013), rat (Li et al., 2013a, 2013b), and human (Cong et al., 2013;
Jinek et al., 2013; Mali et al., 2013). Impressively, by directly
injecting Cas9 mRNA and single-guide RNAs (sgRNAs) into
zygotes, mice or rats carryingmutations in transgenes ormultiple
endogenous genes can be generated in one step (Li et al., 2013a,
2013b; Shen et al., 2013; Wang et al., 2013; Yang et al., 2013),
indicating that the CRISPR-Cas9 system can be used as an
effective tool for genome engineering (Gaj et al., 2013). Neverthe-
less, successful correction of disease-causing mutations in
animal models via the CRISPR-Cas9 system has not yet been
demonstrated. In this study, we report the efficient correction of
a mutant gene in a mouse disease model by zygote injection of
CRISPR-Cas9, and we report subsequent successful transmis-
sion of the corrected trait to the next generation.CellWe chose a mouse model of dominant cataract disorder
caused by a defined mutation in the Crygc gene (Zhao et al.,
2010). These mice carry a 1 bp deletion in exon 3 of Crygc.
This mutation leads to a stop codon at the 76th amino acid
(Figure 1A) and thus the production of truncated gC-crystallin,
resulting in nuclear cataracts (Figure 1B) in both homozygous
and heterozygous mutant mice at weaning (Zhao et al., 2010).
We first tested the feasibility of CRISPR-Cas9-mediated genetic
repair at the cellular level. To this end, we designed five sgRNAs
targeting different regions in the mutant Crygc gene. sgRNA-1,
sgRNA-2, and sgRNA-3 were designed to target regions span-
ning the site of 1 bp deletion in mutant allele (Figure 1C and Sup-
plemental Experimental Procedures available online). sgRNA-4
was designed to target the region immediately downstream of
the 1 bp deletion, which we reasoned might be highly specific
for the mutant allele due to the fact that the 1 bp deletion in the
mutant allele produced a neo-protospacer adjacent motif (neo-
PAM) that is not present in the WT allele (Figure 1C and Supple-
mental Experimental Procedures). sgRNA-5 targeted the normal
sequence upstream of the deletion (Figure 1C and Supplemental
Experimental Procedures). In preliminary experiments, we
investigated the specificity of sgRNAs by separately transfecting
plasmids expressing both the mammalian-codon-optimized
Cas9 and each of the five sgRNAs into WT E14 embryonic
stem cells (ESCs) (Cong et al., 2013; Mali et al., 2013). For
each sgRNA, PCR products corresponding to the putative target
region were amplified from the resulting ESC clones. The results
showed that sgRNA-2 and sgRNA-5 efficiently targeted the WT
alleles and led to nonhomologous end joining (NHEJ)-mediated
mutations of the Crygc gene, while sgRNA-1 and sgRNA-3 did
so much less frequently (Table S1). By contrast, no mutation
was detected in ESC clones transfected with sgRNA-4 (Table
S1). We performed similar experiments in heterozygous mutant
ESCs (termed mCrygc ESCs) and found that all of the sgRNAs
could induce cleavage at the mutant Crygc allele (Table S1).
Consistent with the results from the E14 ESCs, we found that
sgRNA-2 and sgRNA-5 targeted both the WT and mutant alleles
in mCrygc ESCs, while the other three sgRNAs only targeted the
mutant allele. Importantly, while all of the sgRNAs could induceStem Cell 13, 659–662, December 5, 2013 ª2013 Elsevier Inc. 659
Figure 1. CRISPR-Cas9-Mediated Gene Correction in a Cataract Mouse Model
(A) The sequence of themutantCrygc gene. The cataract phenotype is induced by 1 bp deletion in exon 3 ofCrygc. This mutation leads to a stop codon at the 76th
amino acid and thus the production of the truncated gC-crystallin.
(B) The eyes of Crygc/ mutant mouse display cataract phenotypes compared to normal eyes of BALB/c control mouse.
(C) Schematic of the Cas9-sgRNA-targeting sites in mutant Crygc gene. Blue lines label the sgRNA-targeting sequences.
(D) Schematic for a gene correction via homology-directed repair (HDR) induced by the CRISPR-Cas9 system using normal allele on the homologous
chromosome as a template. sgRNA-4 targeting site is labeled in blue and the PAM is marked in red.
(E) Outline of one-step correction of a genetic defect in cataract mouse model. The heterogeneous F1 pups delivered fromWT female mice (B6D2F1) mated with
Crygc/mice bear cataracts. Uponmicroinjections of Cas9mRNA and sgRNA-4 into heterogeneous zygotes carryingmutantCrygc allele, some of the embryos
develop to term with a normal phenotype.
(F) The sequences of theCrygc gene inmice carrying CRISPR-Cas9-induced genemodifications. Insertions are indicatedwith (+), deletions are indicatedwith ().
Small letters represent the inserted nucleotides.
(G) DNA sequence of PCR products amplified from the Crygc gene of a heterogeneous mutant mouse (Crygc+/) and a repaired mouse carrying the corrected
allele induced by HDR after zygote-injection of Cas9 mRNA and sgRNA-4. Two peaks can be observed in the sequence of the control heterogeneous mutant
(Crygc+/) mouse, while the HDR-repaired mouse has only one peak.
(H) A repairedmouse carrying the correct allele induced by HDR and a control heterogeneousmutant (Crygc+/) mouse. The repairedmouse after CRISPR-Cas9-
mediated gene correction is free of cataracts, as measured by the appearance of black lenses compared to the opacity of the lens in control heterogeneous
mutant mouse (Crygc+/).
(I) Histological analysis of lenses prepared from repaired mice via HDR (6 weeks old) and control heterogeneous mutant mice (Crygc+/) (6 weeks old). While the
heterogeneous mutant mouse (Crygc+/) shows vacuole-like degeneration in the equatorial region of the entire eye, the cataract-free mouse exhibits normal
histological features.
(J) Progeny with a repaired mouse (HDR-based) developed from a zygote after injection of Cas9 mRNA and sgRNA-4.
(K) DNA sequencing analysis of progeny. Note that the sequence of PCR products amplified from the Crygc gene shows only one peak in all 13 pups, indicating
that the corrected trait of the repaired mice could be successfully transmitted to the next generation.
See also Figures S1 and S2 and Tables S1 and S2.
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RepairWT allele mutant allele
- 172 157 (91%) 135 22 0 10 2/4 4
Oligo-1 245 213 (87%) 178 29 0 14 4/5 5
Oligo-2 221 190 (86%) 159 27 0 12 5/3 4
Cas9 mRNA and sgRNA-4 targeting mutant allele of Crygc gene were coinjected into fertilized oocytes with or without exogenous oligonucleotides
(Oligo-1 or Oligo-2). The blastocysts derived from the injected embryos were transferred into uteri of pseudopregnant females. Newborn pups
were obtained and genotyped. See also Figures 1, S1, and S2.
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sgRNA-4 could also efficiently promote HDR-based precise
gene editing (16 of 36 ESC clones sequenced) (Table S1),
indicating that Cas9-induced DNA breaks in the mutant Crygc
allele could be repaired through HDR using the normal allele
on the homologous chromosome as a template (Figure 1D).
Taken together, these data suggest that sgRNA-4 specifically
targets the mutant allele; this effect is likely due to the neo-
PAM contained in the mutant allele. We thus selected sgRNA-4
for our subsequent targeting experiments.
We next asked whether the genetic defect in the cataract
mouse model could be corrected at the organism level (defined
as the functional correction of the cataract phenotype) by
injection of CRISPR-Cas9 into zygotes (Shen et al., 2013;
Wang et al., 2013). Cas9 mRNA and sgRNA-4 were coinjected
into the cytoplasm of zygotes that were harvested from
B6D2F1 females mated with homozygous cataract males
(Figure 1E). The injected zygotes developed into blastocysts at
a rate of 91% (Table 1), indicating a low toxicity of the injected
RNAs. Of the 135 transferred blastocysts that were derived after
the injection, a total of 22 live pups were born (Table 1). Upon
DNA sequencing analysis, we identified 10mice carrying genetic
modifications of the mutant allele (Figure 1F). We failed to detect
any gene editing events in the WT allele of these gene-modified
mice, confirming the specificity of sgRNA-4 in targeting the
mutant allele. Similar to our previous observations in ESCs,
gene-editing events induced by the CRISPR-Cas9 system
included NHEJ-mediated insertions and deletions (6 of 10
mice) and HDR-mediated repair (4 of 10 mice) (Figures 1F and
1G). As expected, all four mice that carried the corrected allele
induced by HDR were free of cataracts, as measured by the
appearance of black lenses compared to the opacity of the
lens in control mice developed from heterozygous mutant
embryos (20 of 20 mice) (Figure 1H). Interestingly, two of the
six mice that carried NHEJ-mediated insertions or deletions
also displayed normal lenses (Figure 1F and Figure S1A).
An analysis of the nucleotide sequences of the mutant allele
in these two mice revealed that the cataract phenotype is likely
corrected by the new insertion of one nucleotide in one case or
the new net deletion of five nucleotides in another, both resulting
in the restoration of the correct open reading frame for the
WTgC-crystallin (Figure 1F and Figure S1B).
Next, we asked whether supplying an exogenous WT single-
stranded DNA oligo (termed Oligo-1) would lead to increased
efficiency of HDR-mediated precise genome repair by coinject-
ing Cas9 mRNA, sgRNA-4, and Oligo-1 into the cytoplasm ofCellheterozygous cataract mutation-bearing zygotes (Figures S2A
and S2B and Supplemental Experimental Procedures). From
this set of experiments, a total of 29 live pups were born from
178 transferred blastocysts (Table 1). DNA sequencing results
(Figure S2C) showed that 14 mice carried gene modifications
of the mutant allele. Of these, nine were free of cataracts (Fig-
ure S2D), a frequency similar to the case of injection of Cas9
mRNA and sgRNA-4 (9/29 versus 6/22). Further analysis of
DNA sequences showed that five of these nine cataract-free
mice carried a corrected Crygc gene derived from HDR. The
remaining four mice were apparently repaired by NHEJ, with
either a new insertion of one nucleotide (two pups) or new dele-
tions of 2+3n nucleotides (two pups) (Figure S2C), restoring the
correct open reading frame in all cases. To dissect whether the
CRISPR-Cas9-induced HDRutilized information from the normal
allele on the homologous chromosome or the exogenous oligo
template, we designed a Crygc oligo (termed Oligo-2) harboring
two synonymous mutations (Supplemental Experimental Proce-
dures); this oligo would allow us to discriminate the origin of the
recombination template (Figure S2E). A total of 27 live pups were
born from 159 transferred blastocysts; of these, 9 were free of
cataracts (Table 1). Of the four mice cured via HDR, we found
that three of them carried modified Crygc genes with a DNA
sequence that was same as the exogenous oligo, and the re-
maining one had a DNA sequence identical to that of the WT
allele (Figures S2F and S2G). Taken together, our data suggest
that while supplying exogenous oligos may not be necessary,
the exogenous oligonucleotide could serve as an optional tem-
plate for repairing the mutant gene, especially when the endog-
enous allele cannot be used as the template (as in homozygous
genetic diseases).
In this study, 24 mice were cured of cataracts using the
CRISPR-Cas9 system. To further confirm the correction of the
disease, we performed histological analysis of lenses prepared
from repaired and control cataract mice. As shown in Figure 1I
and Figure S2H, control cataract mice showed pathological
changes in the equatorial region of their entire eyes, but the
cataract-free mice that were cured via HDR or NHEJ-mediated
gene editing (two or three mice, respectively) exhibited normal
histological features. One major hindrance to the therapeutic
application of the CRISPR-Cas9 system is the potential for off-
target mutations; we therefore examined off-target effects in
the repaired mice. Given the recent findings that a maximum
level of mismatch that could be tolerated in the ‘‘target’’
sequence is no more than five nucleotides (Fu et al., 2013; Hsu
et al., 2013; Pattanayak et al., 2013), we searched the genomeStem Cell 13, 659–662, December 5, 2013 ª2013 Elsevier Inc. 661
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identity with the authentic target sequence. This led to the iden-
tification of a total of 10 potential ‘‘off-target’’ sites (Table S2).
DNA sequencing of PCR products amplified from these genomic
sites showed no mutations at these loci in the majority of the re-
paired mice (10 out of 12). For the remaining 2 mice, off-target
mutations were detected at 1 of the 10 potential off-target sites
(Table S2). These results are consistent with previous observa-
tions that injection of CRISPR-Cas9 into mouse and rat embryos
results in genetic-modified animals carrying off-target mutations
in only rare instances (Li et al., 2013a, 2013b; Wang et al., 2013;
Yang et al., 2013). Finally, we analyzed the fertility of repaired
mice by mating them with WT mice. Progeny were obtained
from four cataract-free mice carrying the Crygc gene that was
corrected through variousmechanisms (two via HDR using infor-
mation from the endogenous WT allele, one via NHEJ, and one
via HDR using information from Olig-2) (Figure 1J and Figures
S1C and S2I). DNA sequencing of the progeny showed that
the pups carried the repaired Crygc allele originated from their
parents (Figure 1K and Figures S1D and S2J), indicating that
the corrected allele could be successfully transmitted to the
next generation through the germline.
In summary, we have demonstrated that the CRISPR-Cas9
system can be used to cure a genetic disease in mouse by
directly correcting the genetic defect through NHEJ- or HDR-
mediated gene editing. In the future, it would be of interest to
investigate whether similar gene-correction strategies could be
used for mutation correction in a setting related to human dis-
eases, such as human stem cells.SUPPLEMENTAL INFORMATION
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